CA1298549C - COMPOSITIONS CONTENANT DES INHIBITEURS DE L'.alpha.-MANNOSIDASE II DU GOLGI - Google Patents
COMPOSITIONS CONTENANT DES INHIBITEURS DE L'.alpha.-MANNOSIDASE II DU GOLGIInfo
- Publication number
- CA1298549C CA1298549C CA000548176A CA548176A CA1298549C CA 1298549 C CA1298549 C CA 1298549C CA 000548176 A CA000548176 A CA 000548176A CA 548176 A CA548176 A CA 548176A CA 1298549 C CA1298549 C CA 1298549C
- Authority
- CA
- Canada
- Prior art keywords
- interferon
- composition
- swainsonine
- poly
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 34
- 229940079322 interferon Drugs 0.000 claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 51
- 102000014150 Interferons Human genes 0.000 claims abstract description 48
- 108010050904 Interferons Proteins 0.000 claims abstract description 48
- 206010027476 Metastases Diseases 0.000 claims abstract description 37
- 230000009401 metastasis Effects 0.000 claims abstract description 36
- 239000002799 interferon inducing agent Substances 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 230000002062 proliferating effect Effects 0.000 claims abstract description 14
- 208000036142 Viral infection Diseases 0.000 claims abstract description 9
- 230000009385 viral infection Effects 0.000 claims abstract description 9
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 claims description 79
- 229960005566 swainsonine Drugs 0.000 claims description 76
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 19
- 229940047124 interferons Drugs 0.000 claims description 16
- 230000001028 anti-proliverative effect Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000009826 neoplastic cell growth Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 13
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 33
- 210000004881 tumor cell Anatomy 0.000 description 26
- 206010009944 Colon cancer Diseases 0.000 description 16
- 239000003651 drinking water Substances 0.000 description 15
- 235000020188 drinking water Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 4
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108091028690 C-myc mRNA Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010056342 Pulmonary mass Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- -1 lubrican-ts Substances 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000261411 Astragalus glycyphyllos Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 101100293199 Mus musculus Myc gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91248686A | 1986-09-29 | 1986-09-29 | |
| US91248586A | 1986-09-29 | 1986-09-29 | |
| US912,486 | 1986-09-29 | ||
| US912,485 | 1986-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1298549C true CA1298549C (fr) | 1992-04-07 |
Family
ID=27129605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000548176A Expired - Lifetime CA1298549C (fr) | 1986-09-29 | 1987-09-29 | COMPOSITIONS CONTENANT DES INHIBITEURS DE L'.alpha.-MANNOSIDASE II DU GOLGI |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1298549C (fr) |
-
1987
- 1987-09-29 CA CA000548176A patent/CA1298549C/fr not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2263694B1 (fr) | Agent antitumoral renfermant l'inhibiteur de l'histone désacétylase FK228 et l'inhibiteur de la topoisomerase-II, doxorubicine | |
| KR100230514B1 (ko) | 산화질소 형성 또는 내피 유도 이완 인자와 관련된 전신적 저혈압을 억제하기 위한 아르기닌 길항제 | |
| LEGHA et al. | 4′-(9-acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia | |
| JPH01254623A (ja) | スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬 | |
| JP4076230B2 (ja) | 癌の治療 | |
| KR100477910B1 (ko) | 아미노이미다졸카르복사미드및5-아미노또는치환된아미노1,2,3-트리아졸의염을사용한신생물의치료및예방 | |
| US5624908A (en) | Antineoplastic compositions | |
| US5004735A (en) | Pharmaceutical compositions for the inhibition of tumor metastasis | |
| US4857315A (en) | Compositions containing golgi alpha-mannosidase II inhibitors | |
| PL199576B1 (pl) | Zastosowanie jednego lub więcej N-podstawionych indolo-3-glioksylamidów lub ich fizjologicznie tolerowanych soli addycyjnych do wytwarzania leku do leczenia farmaceutycznie opornych nowotworów | |
| CN1294516A (zh) | 含有具有协同作用的蒽环类衍生物与喜树碱衍生物的抗肿瘤组合物 | |
| JPH05500973A (ja) | 化学的組成物 | |
| US6365578B1 (en) | Drug cominbations containing AZT | |
| CA1298549C (fr) | COMPOSITIONS CONTENANT DES INHIBITEURS DE L'.alpha.-MANNOSIDASE II DU GOLGI | |
| WO2000056334A1 (fr) | Utilisation d'iminosucres dans les therapies anti-tumorales | |
| Priestman | Interferons and cancer therapy | |
| Naguib et al. | Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil | |
| JP3064815B2 (ja) | ミエローマ系腫瘍抗癌剤 | |
| Katoh et al. | Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients | |
| JPS62263127A (ja) | 自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置 | |
| Colombini et al. | Retro-orbital late relapse in a child with leukaemia after allogeneic bone marrow transplantation | |
| JP2648176B2 (ja) | 制癌剤 | |
| CN113164474A (zh) | 维奈托克的水溶性高分子衍生物 | |
| US5175005A (en) | Method of controlling lung tumor cell metastasis | |
| KR100499691B1 (ko) | 택솔 및 홍삼산성다당체를 포함하는 항암용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |